Skip to main content
Terug
Watch Compare

IceCure Medical Ltd.

Datakwaliteit: 100%
ICCM
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 0,32
▼ € 0,02 (-5,00%)
Marktkapitalisatie: 27,88 M
Prijs
€ 0,34
Marktkapitalisatie
27,88 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -4,94% annually over 5 years
Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -14,61 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7,61%
Capital efficient — spends only 1,07% of revenue on capex

Groei

Revenue Growth (5Y)
-4,94%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)2,67%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-223,05%
Onder sectorgemiddelde (-53,34%)
ROIC-172,45%
Net Margin-445,61%
Op. Margin-446,70%

Veiligheid

Debt / Equity
0,02
Onder sectorgemiddelde (0,31)
Current Ratio1,18
Interest CoverageN/A

Waardering

PE (TTM)
-1,85
Onder sectorgemiddelde (-1,47)
P/B Ratio9,64
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,9 -1,5
P/B 9,6 1,6
ROE % -223,1 -53,3
Net Margin % -445,6 -41,5
Rev Growth 5Y % -4,9 1,8
D/E 0,0 0,3

Koersdoel Analisten

2 analisten
Strong Buy
Huidig
€ 0,32
+743.7%
Koersdoel
€ 2,73
€ 2,45
€ 2,73
€ 3,00
Vooruitzicht
Forward K/W -4,04
Forward WPA -€ 0,08
Omzet Sch. 13,94 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,08
-€ 0,08 – -€ 0,08
 13,94 M 1
FY2026 -€ 0,12
-€ 0,12 – -€ 0,12
 7,93 M 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,04 -€ 0,06 -50,0%
Q32025 -€ 0,06 -€ 0,06 -9,1%
Q22025 -€ 0,07 -€ 0,06 +7,7%
Q12025 -€ 0,08 -€ 0,06 +25,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 2,67% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -4,94% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,38 M Net Income (TTM) -15,06 M
ROE -223,05% ROA -116,06%
Gross Margin 36,28% Operating Margin -446,70%
Net Margin -445,61% Free Cash Flow (TTM) -14,61 M
ROIC -172,45% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 1,18
Interest Coverage N/A Asset Turnover 0,26
Working Capital 1,38 M Tangible Book Value 2,89 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,85 Forward P/E N/A
P/B Ratio 9,64 P/S Ratio 8,25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -52,41%
Market Cap 27,88 M Enterprise Value 22,55 M
Per Share
EPS (Diluted TTM) 0,24 Revenue / Share 0,04
FCF / Share -0,18 OCF / Share -0,18
EPS CAGR (1Y) -20,00% EPS CAGR (5Y) -9,00%
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,07% FCF Conversion 97,03%
SBC-Adj. FCF -16,87 M Growth Momentum 7,61

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,38 M 3,29 M — 3,09 M 4,14 M
Net Income -15,06 M -15,32 M -14,65 M -16,98 M -9,90 M
EPS (Diluted) 0,24 0,30 0,32 0,46 0,35
Gross Profit 1,23 M 1,45 M 1,30 M 1,45 M 2,20 M
Operating Income -15,09 M -15,70 M -15,58 M -16,74 M 9,72 M
EBITDA — — — — —
R&D Expenses 7,43 M 7,10 M 8,27 M 9,12 M 5,88 M
SG&A Expenses — — — 735.000,0 177.000,0
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13,89 M 12,58 M 16,41 M 30,19 M 32,28 M
Total Liabilities — — — — —
Shareholders' Equity 9,05 M 6,90 M 12,16 M 25,42 M 26,96 M
Total Debt 13.000,0 — — — —
Cash & Equivalents 8,90 M 7,56 M 10,53 M 23,66 M 25,62 M
Current Assets 12,61 M 10,75 M 14,18 M 28,13 M 30,32 M
Current Liabilities 4,82 M 5,51 M 3,87 M 4,34 M 4,02 M